# Retatrutide renal-impairment study record updated

> ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.

- Evidence object: `story:retatrutide-renal-impairment-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/objects/retatrutide-renal-impairment-study-updated-v1.json
- Content SHA-256: `6030224da72caa7740907f361f522b68463f49c4d215da3e9ce8eee9b903b813`

## Claims and source pins

### Headline

Retatrutide renal-impairment study record updated ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

### Summary

ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

### Paragraph 1

ClinicalTrials.gov lists the NCT06297603 record under Eli Lilly and Company. Its overall recruitment status was shown as active, not recruiting when PeptideScanner reviewed the record. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

### Paragraph 2

The registry shows 2026-07-20 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct06297603-v25`](#source-ctg-nct06297603-v25))

## Sources

<a id="source-ctg-nct06297603-v25"></a>
- **Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06297603?a=25&tab=history) (`ctg-nct06297603-v25`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Retatrutide renal-impairment study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/objects/retatrutide-renal-impairment-study-updated-v1.json SHA-256: 6030224da72caa7740907f361f522b68463f49c4d215da3e9ce8eee9b903b813.